NCODA Logo

Neratinib (Nerlynx®) Diarrhea Management

Written by: Eric Dallara, RPh, New England Cancer Specialist Download Here Description:  Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the neratinib arm in which antidiarrheal prophylaxis was not protocol...

Durvalumab (Imfinzi®) Therapy Overview

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss the overall management of durvalumab and immune-mediated adverse events in the treatment of Stage III unresectable NSCLC and first-line extensive stage small cell...

Selinexor (Xpovio®) Patient Management

Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center Download Here Description: This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed,...